The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: an analysis of RTOG data

被引:54
作者
Emami, B
Mirkovic, N
Scott, C
Byhardt, R
Graham, MV
Andras, EJ
John, M
Herskovic, A
Urtasun, R
Asbell, SO
Perez, CA
Cox, J
机构
[1] Loyola Univ, Med Ctr, Dept Radiat Oncol, Maywood, IL 60153 USA
[2] Radiat Therapy Oncol Grp, Philadelphia, PA USA
[3] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[4] Phelps Cty Reg Med Ctr, Rolla, MO USA
[5] Radiat Oncol Ctr, Sacramento, CA USA
[6] Canc Ctr St Agnes, Fresno, CA USA
[7] NW Community Hosp, Arlington Hts, IL USA
[8] Cross Canc Ctr, Edmonton, AB, Canada
[9] Albert Einstein Med Ctr, Philadelphia, PA 19141 USA
[10] Washington Univ, Sch Med, St Louis, MO USA
[11] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
关键词
non-small cell lung cancer; radiotherapy; regional nodes; field borders; in-field progression; survival;
D O I
10.1016/S0169-5002(03)00228-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate in-field progression and survival of patients with unresectable non-small cell lung cancer (NSCLC) in relation to adequacy of coverage of thoracic regional nodal areas in the radiotherapy volume. Materials and methods: A total of 1705 patients from four large RTOG trials (78-11, 79-17, 83-11 and 84-07) were analyzed for this purpose. For each of these trials, the dose delivered to nodal regions was recorded and an assessment of adequacy of field borders was made. Each nodal site was assessed for progression, defined as in-field or out-of-field. In patients who had adequate;: borders on nodal regions, the results were analyzed according to the dose delivered. Results: The majority (74%) of patients were between the age of 55-75. Forty-six percent of the patients had KPS of 60-80 and 52% had KPS of 90-100. Sixty percent of patients had a weight loss of less than 5% in the 6 months prior to diagnosis. Deviations from the protocol in field borders (borders not per protocol) were most frequent for the contralateral hilum (25.2%) and least frequent in the ipsilateral hilum (6.3%). The adequacy of ipsilateral hilar coverage was important for preventing the in-field progression (11.6 vs. 22% for adequately vs. inadequately covered ipsilateral hilum, respectively, P = 0.01), however, did not influence the 2-year-survival (35 vs. 37%) or median survival (1.3 vs. 1.1 year). Neither the in-field progression nor the 2-year-survival were affected by adequacy of nodal coverage in the mediastinum, ipsilateral supraclavicular area and contralateral hilum, even when different doses were analyzed. Conclusion: These data suggest that elective irradiation of mediastinal, contralateral hilar and supraclavicular Lymph nodes may not be necessary in the treatment of unresectable NSCLC. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:207 / 214
页数:8
相关论文
共 29 条
[1]   THE INFLUENCE OF FIELD SIZE AND OTHER TREATMENT FACTORS ON PULMONARY TOXICITY FOLLOWING HYPERFRACTIONATED IRRADIATION FOR INOPERABLE NONSMALL CELL LUNG-CANCER (NSCLC) - ANALYSIS OF A RADIATION-THERAPY ONCOLOGY GROUP (RTOG) PROTOCOL [J].
BYHARDT, RW ;
MARTIN, L ;
PAJAK, TF ;
SHIN, KH ;
EMAMI, B ;
COX, JD .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 27 (03) :537-544
[2]   A PHASE-I/II STUDY TO EVALUATE ACCELERATED FRACTIONATION VIA CONCOMITANT BOOST FOR SQUAMOUS, ADENO, AND LARGE-CELL CARCINOMA OF THE LUNG - REPORT OF RADIATION-THERAPY ONCOLOGY GROUP 84-07 [J].
BYHARDT, RW ;
PAJAK, TF ;
EMAMI, B ;
HERSKOVIC, A ;
DOGGETT, RS ;
OLSEN, LA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 26 (03) :459-468
[3]   Involved-field radiotherapy alone for early-stage non-small-cell lung cancer [J].
Cheung, PCF ;
Mackillop, WJ ;
Dixon, P ;
Brundage, MD ;
Youssef, YM ;
Zhou, S .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (03) :703-710
[4]   A RANDOMIZED PHASE-I/II TRIAL OF HYPERFRACTIONATED RADIATION-THERAPY WITH TOTAL DOSES OF 60.0 GY TO 79.2 GY - POSSIBLE SURVIVAL BENEFIT WITH GREATER-THAN-OR-EQUAL-TO 69.6 GY IN FAVORABLE PATIENTS WITH RADIATION-THERAPY ONCOLOGY GROUP STAGE-III NON-SMALL-CELL LUNG-CARCINOMA - REPORT OF RADIATION-THERAPY ONCOLOGY GROUP 83-11 [J].
COX, JD ;
AZARNIA, N ;
BYHARDT, RW ;
SHIN, KH ;
EMAMI, B ;
PAJAK, TF .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (09) :1543-1555
[5]  
FLETCHER GH, 1973, BRIT J RADIOL, V46, P1
[6]   Systematic nodal dissection in the intrathoracic staging of patients with non-small cell lung cancer [J].
Graham, ANJ ;
Chan, KJM ;
Pastorino, U ;
Goldstraw, P .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1999, 117 (02) :246-251
[7]   Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) [J].
Graham, MV ;
Purdy, JA ;
Emami, B ;
Harms, W ;
Bosch, W ;
Lockett, MA ;
Perez, CA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 45 (02) :323-329
[8]   Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: Update of a phase I trial [J].
Hayman, JA ;
Martel, MK ;
Ten Haken, RK ;
Normolle, DP ;
Todd, RF ;
Littles, JF ;
Sullivan, MA ;
Possert, PW ;
Turrisi, AT ;
Lichter, AS .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) :127-136
[9]   Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer - Results of a prospective randomized trial [J].
Izbicki, JR ;
Passlick, B ;
Pantel, K ;
Pichlmeier, U ;
Hosch, SB ;
Karg, O ;
Thetter, O .
ANNALS OF SURGERY, 1998, 227 (01) :138-144
[10]   Local irradiation alone for peripheral Stage I lung cancer: Could we omit the elective regional nodal irradiation? [J].
Krol, ADG ;
Aussems, P ;
Noordijk, EM ;
Hermans, J ;
Leer, JWH .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 34 (02) :297-302